Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: A meta-analysis of randomized controlled trials

Drugs

Volumn 72, Issue 11, 2012, Pages 1521-1533

  Liu, Lin Lin ^a   Jiang, Yi ^a   Wang, Li Ning ^a   Yao, Li ^a   Li, Zi Long ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cyclophosphamide; Lupus nephritis; Mycophenolate mofetil; Systemic lupus erythematosus

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ALOPECIA; AMENORRHEA; DEATH; DIARRHEA; GASTROINTESTINAL SYMPTOM; HUMAN; INDUCTION CHEMOTHERAPY; KIDNEY FAILURE; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864243872     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11635030-000000000-00000     Document Type: Review

References (34)

1. Harley JB, Kelly JA, Kaufman KM. Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol 2006 Oct; 28 (2): 119-30 (Pubitemid 44526313)
2. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999 Feb; 10 (2): 413-24 (Pubitemid 29068083)
3. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003 Sep; 82 (5): 299-308 (Pubitemid 37229465)
4. Bagavant H, Kalantarinia K, Scindia Y, et al. Novel therapeutic approaches to lupus glomerulonephritis: translating animal models to clinical practice. Am J Kidney Dis 2011 Mar; 57 (3): 498-507
5. Navaneethan SD, Viswanathan G, Strippoli GF. Treatment options for proliferative lupus nephritis: an update of clinical trial evidence. Drugs 2008; 68 (15): 2095-104
6. Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 2004; 13 (5): 366-71 (Pubitemid 38788498)
7. Fulton B, Markham A. Mycophenolate mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996 Feb; 51 (2): 278-98
8. Snell GI, Westall GP. Immunosuppression for lung transplantation: evidence to date. Drugs 2007; 67 (11): 1531-9 (Pubitemid 47267296)
9. Appel A, Appel G. An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol 2009 Mar; 5 (3): 132-42
10. Quaglia M, Stratta P. Idiopathic membranous nephropathy: management strategies. Drugs 2009 Jul; 69 (10): 1303-17
11. Li X, Ren H, Zhang Q, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 2012 Apr; 27 (4): 1467-72
12. El-Shafey EM, Abdou SH, Shareef MM. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin ExpNephrol 2010 Jun; 14 (3): 214-21
13. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009 May; 20 (5): 1103-12
14. Wang J, Hu W, Xie H, et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007; 16 (9): 707-12 (Pubitemid 47517865)
15. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005 Nov; 353 (21): 2219-28 (Pubitemid 41697285)
16. Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005 Oct; 10 (5): 504-10 (Pubitemid 41727277)
17. Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005 Apr; 16 (4): 1076-84 (Pubitemid 41710318)
18. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions, version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008 [online]. Available from URL: http://www.cochrane-handbook. org.[Accessed 2010 Mar 1]
19. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009 Jul; 339: b2535
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 Sep; 7 (3): 177-88 (Pubitemid 17189972)
21. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004 Feb; 15 (2): 241-50 (Pubitemid 38140764)
22. Houssiau FA. Cyclophosphamide in lupus nephritis. Lupus 2005; 14 (1): 53-8 (Pubitemid 40216069)
23. Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol 2010; 21 (12): 2028-35
24. Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006 Apr; 119 (4): 355.e25-33
25. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006; 8 (6): R182
26. WalshM, JamesM, JayneD, et al.Mycophenolatemofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin JAmSoc Nephrol 2007 Sep; 2 (5): 968-75
27. Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007 Jul; 22 (7): 1933-42 (Pubitemid 47244763)
28. Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol 2011 Jan; 38 (1): 69-78
29. Mak A, Cheak AA, Tan JY, et al. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford) 2009 Aug; 48 (8): 944-52
30. Kamanamool N, McEvoy M, Attia J, et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore) 2010 Jul; 89 (4): 227-35
31. Ting RZ, Luk AO, Chan JC. Treatment and landmark clinical trials for renoprotection. Contrib Nephrol 2011; 170: 184-95
32. Sa nchez RA, Traballi CA, Marco EJ, et al. Effects of ACE inhibition on renal haemodynamics in essential hypertension and hypertension associated with chronic renal failure. Drugs 1991; 41 Suppl. 1: 25-30
33. Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005; 65 Suppl. 2: 29-39 (Pubitemid 41480578)
34. Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials: a critical overview. Lupus 1998; 7 (9): 622-9 (Pubitemid 29008229)